CERO (CERo Therapeutics) שולי הרווח הגולמי

סמל תאגידי ולוגו של CERo Therapeutics Holdings (CERO)

The success of CERo Therapeutics is based on the efficacy of phagocytic T-cells and the scaling of blood therapy. High demand for innovative immune reprogramming methods confirms the potential of this market niche. A lack of recurring revenue makes the company dependent on investments and grants. The gross profit margin demonstrates the business's resilience, where the value 0.00 describes the current level of profitability.

CERO - שולי רווח גולמי cero.bio בטווח 21.02.2024 - 08.11.2025

פילוחי מדדים מקיפים ואנליטיקה עבור cero.bio (CERO)

הערכת שווי פונדמנטלית:CERo Therapeutics (CERO)
מוצרים מיוצרים של CERo Therapeutics

The metric is calculated as the difference between total revenue and direct production costs, revealing the efficiency of cost-of-goods-sold management. This indicator determines the portion of profit available to cover operating expenses and R&D investments. In the context of developing cell therapy in the US, which is shielded from geopolitical risks, the gross margin trend reflects the internal technological resilience of CERo Therapeutics (CERO) without the influence of external trade conflicts.